MedTrace Logo

Lifestyle Counselling as Secondary Prevention in Patients With Minor Stroke and Transient Ischemic Attack

NCT03648957 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-03-03

No results posted yet for this study

Summary

Interventions to improve health behaviour in patients with resent acute stroke are not well established. This study will evaluate the feasibility and effect of an early initiated counselling intervention targeting smoking, physical activity, and adherence to preventive medication, with regular follow-up sessions, in patients with acute minor stroke or transient ischemic attack who are discharged home.

Conditions

  • Stroke, Ischemic
  • Stroke Hemorrhagic
  • Transient Ischemic Attack

Interventions

BEHAVIORAL

Lifestyle counselling

First behavioral counselling session will be conducted before discharge and follow-up session will be offered with 3-4 weeks intervals either by telephone or in the outpatient clinic.

BEHAVIORAL

Usual care

Usual stroke care discharge session; including written and verbal encouragement to a healthy lifestyle.

DEVICE

Activity tracker

Participants are encouraged to wear a activity tracker to monitor their physical activity

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Metropolitan University College

    collaborator OTHER

  • Nordsjaellands Hospital

    lead OTHER

Principal Investigators

  • Thomas Christensen, MD · Department of Neurology, Nordsjællands Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2020-04-08
Completion
2021-02-28

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03648957 on ClinicalTrials.gov